Welcome to our dedicated page for EXICURE SEC filings (Ticker: XCUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exicure, Inc. filings document a clinical-stage biotechnology issuer centered on burixafor (GPC-100) and hematologic disease development, along with the corporate governance and financing matters that support that operating structure. Its 8-K reports include financial results, liquidity disclosures, research and development expense trends, and clinical or regulatory events tied to the burixafor Phase 2 program and related license and collaboration arrangements.
Other filings record director and executive management changes, audit committee appointments, material agreements, shareholder voting matters, and capital-structure disclosures. Exicure's public records also describe intercompany financing activity involving KC Creation Co., Ltd. convertible bonds and the company's acquisition-related shift from its historical nucleic acid therapy platform to a hematologic-disease pipeline.
Exicure HiTron Inc., a more than 10% owner of EXICURE, INC., reported acquiring a total of 623,275 common shares in a series of code J transactions on June 23, 24, 26 and July 8, 2026 at $4.50 per share. According to the footnote, these acquisitions reflect shares returned to Exicure HiTron under share transfer amendment agreements that reduced the number of shares previously transferred to certain transferees; voting and dispositive power reverted only when the transfer agent recorded the shares back in its name. Following the latest transaction, Exicure HiTron directly holds 2,222,224 common shares of Exicure.
Exicure HiTron Inc., a South Korean company, filed Amendment No. 6 to its Schedule 13D on Exicure, Inc., revising earlier share transfer transactions. On June 23 and 26, 2026, it entered Share Transfer Amendment Agreements with five prior purchasers that reduced the shares sold and returned an aggregate of 623,277 Exicure common shares.
After these returns were recorded by the transfer agent, Exicure HiTron beneficially owned 2,222,224 shares with sole voting and dispositive power, representing about 34.87% of Exicure’s 6,373,937 shares outstanding as of May 26, 2026. It retained aggregate proceeds of approximately KRW 4,160,554,000 from the revised transactions. Two other purchasers continue to hold 487,834 shares previously acquired, and Exicure HiTron may seek recovery of those shares under pledge arrangements.
Exicure, Inc. is reshaping its board and governance structure. Director Ham Jung Kyu resigned from the Board effective June 30, 2026. The Board size will increase from five to six directors on the same date, expanding the number of Class III directors.
To fill the resulting seats, the Board appointed Han Eui Seok and Go Jin Young as Class III directors, effective June 30, 2026. The Board determined that Mr. Han qualifies as an independent director under Nasdaq Listing Rule 5605(a)(2), while Mr. Go does not, due to his anticipated role as a non-independent director.
The Board also created a new Compensation Committee, effective June 30, 2026, naming Mr. Han as Chair and Dongho Lee as a member. The company states there are no related-party transactions, special arrangements, or family relationships involving the new directors that require disclosure.
Exicure, Inc. reported that Nasdaq notified the company on May 28, 2026 that it was out of compliance with Nasdaq Listing Rule 5250(c)(1) because its Form 10-Q for the quarter ended March 31, 2026 was filed late.
The delay was attributed to extra time needed after changes in Exicure’s financial reporting personnel and related procedures. Exicure filed the delayed Form 10-Q on May 29, 2026 and believes this filing brings it back into compliance with the Nasdaq listing rule.
The company describes itself as a biotechnology business that has restructured, suspended prior clinical and development activities, and is now exploring strategic alternatives. Its lead program, obtained through a January 2025 acquisition, is being evaluated for improving stem cell mobilization in multiple myeloma, sickle cell disease, and to support cell and gene therapy.
Exicure, Inc. reported a net loss of $1.8 million for the three months ended March 31, 2026, compared with net income of $3.0 million a year earlier. The swing was driven by the absence of a prior-year $6.0 million lease-termination gain and lower other income, partly offset by sharply reduced operating expenses.
The company generated no revenue, with research and development expense falling to $0.3 million and general and administrative expense to $1.3 million. Cash and cash equivalents were $2.6 million and stockholders’ equity $2.1 million as of March 31, 2026, while total liabilities reached $10.7 million, including $7.0 million of contingent consideration tied to the GPCR USA acquisition.
Management states there is substantial doubt about Exicure’s ability to continue as a going concern, citing ongoing losses, limited cash, and the need for additional financing to support operations and strategic alternatives. The company is exploring transactions around its GPCR USA oncology program, which completed a Phase 2 trial in January 2026, and expects to pay a $1.0 million milestone to GPCR in common stock.
Exicure discloses material weaknesses in internal control over financial reporting, multiple ongoing legal matters, and recent Nasdaq notices related to listing-rule compliance, including a deficiency triggered by the delayed filing of this report. Management indicates it is working to remediate controls and regain and maintain compliance, but acknowledges continued listing and financing uncertainties.
Exicure, Inc. submitted a Form 12b-25 notifying the SEC that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 and expects to file within the five‑day grace period under Exchange Act Rule 12b-25.
The company states preliminary, unaudited results: total revenue $0 for the quarter, an expected net loss of approximately $1,827,911 for the three months ended March 31, 2026 versus approximately $3,010,000 for the three months ended March 31, 2025. It expects cash and cash equivalents of approximately $2,504,054 as of March 31, 2026, versus approximately $3.7 million as of December 31, 2025. Management notes the figures are preliminary and subject to completion of its financial review.
Exicure, Inc. reported governance and management changes, including a new director and a new Chief Operating Officer. These updates focus on strengthening board oversight and operational leadership.
The Board appointed Yoontae Han as director and Audit Committee member, with an annual retainer of $20,000. It also named Dongho Lee as Chair of the Audit Committee. Separately, effective April 9, 2026, Exicure appointed Young Seung Ko, age 50, as Chief Operating Officer and amended its executive services agreement with Innocircle Advisors Inc. to add an extra monthly fee of $10,000 for COO services.
Exicure, Inc. has obtained preliminary court approval for a global settlement of stockholder derivative matters tied to previously disclosed litigation over past handling of research data and disclosures. The settlement covers actions in federal courts in Illinois and Delaware plus a stockholder demand to the board.
Under the proposed terms, Exicure will adopt and maintain a package of corporate governance reforms for at least four years, including a new board-level Research and Data Integrity Oversight Committee and a management-level Disclosure Committee. Defendants’ insurers, rather than the company, have agreed to pay $675,000 in plaintiffs’ attorneys’ fees and expenses, subject to final court approval. A settlement hearing is scheduled for June 2, 2026, and current stockholders as of March 18, 2026 may object by written submission ahead of that date.
Exicure, Inc. reported a change on its Board of Directors. On March 25, 2026, director Sangjin Yeo submitted his resignation from the Board and the Audit Committee, effective March 27, 2026. The company stated that his resignation did not result from any disagreement regarding its operations, policies, or practices. The report was signed on behalf of Exicure by Chief Executive Officer Jung Soo Kim.
Exicure, Inc. reports that it has halted its historical biotech R&D, sold essentially all prior intellectual property, and is now focused on exploring strategic alternatives, including acquisitions and partnerships, potentially outside biotechnology and with an emphasis on Asia.
At December 31, 2025, cash and cash equivalents were about $3.7 million, with a 2025 net loss of $4.9 million and an accumulated deficit of $223.0 million, leading to “substantial doubt” about its ability to continue as a going concern without near‑term financing.
The company acquired GPCR Therapeutics USA Inc. in January 2025; GPCR USA completed a Phase 2 trial in January 2026, and Exicure plans a $1.0 million milestone payment in stock in 2026. HiTron owns about 25% of common stock, increasing governance influence concerns. Risks include Nasdaq delisting, significant legal proceedings and settlements, difficulties redeeming $2.090 million of convertible notes, unpaid rent disputes of about $0.7 million, and limited internal controls and cybersecurity resources.